MAPT and Alzheimer disease: We utilized hiPSC-derived neurons and a genome editing technology approach to decipher the potential therapeutic effects of HH-F3 on the release of Aβ and the hyperphosphorylation of Tau (Figs. 3 and 4), which are the hallmarks of AD pathology.